<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04134130</url>
  </required_header>
  <id_info>
    <org_study_id>2019-01942</org_study_id>
    <nct_id>NCT04134130</nct_id>
  </id_info>
  <brief_title>The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer</brief_title>
  <official_title>Case Control Study Regarding the Role of Follicle Stimulating Hormone in Chemically Castrated Young Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swedish Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ALF Swedish Government Grant</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to elucidate if FSH can have testosterone like effects, samples from young,
      non-smoking healthy volunteers, with normal body mass index, and with pharmacologically
      induced gonadotropin deficiency will be studied regarding their capacity to induce prostate
      specific antigen (PSA), which normally is regulated by testosterone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Normally, prostate specific antigen (PSA), which is a marker for prostate disease and
      progression, is exclusively produced in response to testosterone. In order to elucidate if
      follicle stimulating hormone (FSH) can have testosterone like effects, samples from n=30
      non-smoking healthy volunteers, 20-30 years of age and with normal body mass index (20-25)
      with pharmacologically induced gonadotropin deficiency will be studied. The men are currently
      recruited and during 5 weeks undergoing:

        1. Pharmacologically induced gonadotropin deficiency w 1-3;

        2. FSH-treatment of 50% (group A), w 1-5;

        3. Testosterone (T) treatment of all (group A and B) w 4-5;

        4. End and follow up after 5 weeks.

      A subcutaneous injection with the GnRH antagonist degarelix (240 mg¸ Ferring GmbH Wittland,
      Kiel, Germany) results in drop of both FSH and LH-induced testosterone. Half of the men will
      get recombinant FSH (300 IU; Gonal-f, Merck Serrono S.A. Aubonne, Schweiz) back, whereas 50%
      will not. Three weeks thereafter, the full spectrum of FSH dependent changes occur and are
      reflected in blood. From this occasion testosterone (Nebido, Ferring GmbH Wittland, Kiel,
      Germany) will be given to all participants to diminish the side-effects of the castration.
      Blood samples are collected at start, after 3 wks and after 5 wks. At that point also a
      follow up is undertaken. This experimental design will provide samples from each individual
      during normal conditions, during castration, and after a standardised dose of FSH.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized case control study: one arm with FSH treatment for 5 weeks and one arm without FSH.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA-concentration</measure>
    <time_frame>5 weeks</time_frame>
    <description>Prostate marker</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FSH dependent proteins</measure>
    <time_frame>5 weeks</time_frame>
    <description>Proteins identified by spectrophotometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Prostate Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>GnRH antagonist + FSH + testosterone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>At the start of the study: 240 mg of the gonadotropin releasing hormone antagonist Degarelix (Ferring GmbH, Wittland, Kiel, Germany) + recombinant FSH (Gonal-f, Merck Serrono S.A. Aubonne, Schweiz), 300 IU every second day for 5 weeks.
After 3 weeks: 1000 mg testosterone once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GnRH antagonist + testosterone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>At the start of the study: 240 mg of the gonadotropin releasing hormone antagonist Degarelix (Ferring GmbH, Wittland, Kiel, Germany).
After 3 weeks: 1000 mg testosterone (Nebido, Bayer AB, Solna, Sweden) once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix 120 MG [Firmagon]</intervention_name>
    <description>Two doses of degarelix, 240 mg, subcutaneously once, at study start.</description>
    <arm_group_label>GnRH antagonist + FSH + testosterone</arm_group_label>
    <arm_group_label>GnRH antagonist + testosterone</arm_group_label>
    <other_name>Firmagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector</intervention_name>
    <description>Gonal-f 300 IU subcutaneously 3 times per week for 5 weeks.</description>
    <arm_group_label>GnRH antagonist + FSH + testosterone</arm_group_label>
    <other_name>Gonadotropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Undecanoate</intervention_name>
    <description>One dose 1000 mg testosterone once, after 3 weeks.</description>
    <arm_group_label>GnRH antagonist + FSH + testosterone</arm_group_label>
    <arm_group_label>GnRH antagonist + testosterone</arm_group_label>
    <other_name>Nebido</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Healthy, non-smoking, body mass index 20-25, Exclusion Criteria:
        Medication or drug abuse

        -
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvonne Lundberg Giwercman, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University, dept Translational medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reproductive Medicine Center</name>
      <address>
        <city>Malmö</city>
        <zip>21428</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

